Irish biopharmaceutical firm Allergan has entered into a definitive agreement to acquire US-based medical technology company Zeltiq Aesthetics for $2.475bn.

The acqusition is expected to be immediately accretive and strengthen Allergan's portfolio of medical aesthetics with the addition of Zeltiq's CoolSculpting system.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The US Food and Drug Administration (FDA) cleared the CoolSculpting system to affect appearance through lipolysis or reduction of unwanted fat by utilising a patented cooling technology.

"With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices."

Based on the scientific principle that fat cells are sensitive to cold compared to overlying skin and surrounding tissues, the system is claimed to gently cool targeted fat cells in the body to trigger a natural, controlled removal of fat cells without affecting surrounding tissue.

Allergan chairman and chief executive officer Brent Saunders said: "The acquisition of Zeltiq is highly complementary and strategic to Allergan.

"By adding the best-in-class body contouring CoolSculpting System to our best-in-class facial aesthetics, plastic surgery and regenerative medicine offerings we are creating a world-class aesthetics business.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices, putting Allergan in a unique position to provide expanded customer service, and help meet the needs of patients."

Subject to customary adjustments and approval by the shareholders of Zeltiq, the transaction is expected to be complete by the second half of this year.

It is reported that millions of treatments have been performed by using more than 5,700 CoolSculpting systems in more than 80 countries.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact